MedTrace Logo

Dose Finding Safety Study of VAL201 in Cancer Patients

NCT02280317 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-11-08

Study results available
· View outcomes & findings →

Summary

Dose finding safety study of VAL201 in cancer patients.

Conditions

  • Stage III Prostate Carcinoma
  • Stage IV Prostate Carcinoma

Interventions

DRUG

VAL201

VAL201-001 Sub-cutaneous injection.

Sponsors & Collaborators

  • ValiRx Plc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2020-01-27
Completion
2020-01-27

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02280317 on ClinicalTrials.gov